{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:05:26Z","timestamp":1789401926752,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ccell.2026.08.001","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:04:10Z","timestamp":1789398250000},"page":"1715-1720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular residual disease: Charting a new path for treating resectable solid tumors"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9321-8452","authenticated-orcid":false,"given":"Shin","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadayoshi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Tie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2026.08.001_bib1","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.08.001_bib2","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1038\/s41591-025-04030-w","article-title":"Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2\/3 DYNAMIC-III trial","volume":"31","author":"Tie","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.08.001_bib3","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.08.001_bib4","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41591-026-04428-0","article-title":"Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial","volume":"32","author":"Bando","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.08.001_bib5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.annonc.2022.11.005","article-title":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","volume":"34","author":"Turner","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.08.001_bib6","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1038\/s41591-023-02488-0","article-title":"A synthetic control arm for refractory metastatic colorectal cancer: the no placebo initiative","volume":"29","author":"Yoshino","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.08.001_bib7","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-021-01553-w","article-title":"Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial","volume":"27","author":"Nakamura","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.08.001_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/CLEP.S242097","article-title":"Synthetic and External Controls in Clinical Trials - A Primer for Researchers","volume":"12","author":"Thorlund","year":"2020","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.ccell.2026.08.001_bib9","article-title":"ARCAD-Asia initiative: leveraging yesterday\u2019s data for tomorrow","volume":"2","author":"Takeda","year":"2023","journal-title":"ESMO Gastrointest. Oncol."},{"key":"10.1016\/j.ccell.2026.08.001_bib10","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.annonc.2021.09.016","article-title":"Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project","volume":"32","author":"Vega","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.08.001_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/PO-25-00267","article-title":"Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation","volume":"10","author":"Baden","year":"2026","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ccell.2026.08.001_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114118","article-title":"Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts","volume":"206","author":"Taieb","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ccell.2026.08.001_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pst.1589","article-title":"Use of historical control data for assessing treatment effects in clinical trials","volume":"13","author":"Viele","year":"2014","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.ccell.2026.08.001_bib14","doi-asserted-by":"crossref","first-page":"8664","DOI":"10.1200\/JCO.2005.01.6071","article-title":"Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials","volume":"23","author":"Sargent","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.08.001_bib15","unstructured":"(2024) Combined FDA and Applicants ODAC Briefing Document, Use of Minimal Residual Disease (MRD) as an Endpoint in Multiple Myeloma Clinical Trials 2024 https:\/\/www.fda.gov\/media\/177652\/download."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826003570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826003570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:30:03Z","timestamp":1789399803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610826003570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1535610826003570"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2026.08.001","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular residual disease: Charting a new path for treating resectable solid tumors","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2026.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}